Pharma Pioneer

Bio-Thera Launches BAT6026 OX40 Targeted Monoclonal Antibody Phase IB/IIA Clinical Trial for Moderate to Severe Atopic Dermatitis Patients

31 May 2024
2 min read

Bio-Thera Solutions, a biopharmaceutical firm, has initiated a Phase IA/IIA clinical trial for BAT6026, a monoclonal antibody designed to target OX40, in individuals suffering from moderate to severe atopic dermatitis. The OX40 protein, which is significantly present in activated T cells, is a key player in inflammatory diseases such as atopic dermatitis. BAT6026 works by inhibiting the OX40/OX40L interaction, thereby preventing T cell activation and proliferation, and also by depleting activated OX40+ T cells through an enhanced antibody-dependent cellular cytotoxicity (ADCC) effect. The drug has demonstrated a promising preclinical profile and was found to be safe and well-tolerated in a prior Phase 1 clinical study.
The current multicenter clinical trial aims to evaluate the drug's efficacy and safety, focusing on its impact on safety, tolerability, pharmacokinetics, and initial anti-inflammatory effects. Bio-Thera Solutions, based in Guangzhou, China, is a prominent biopharmaceutical company that specializes in developing innovative treatments for a variety of conditions including cancer, autoimmune diseases, cardiovascular diseases, and eye disorders. The company has several products in late-stage development and has already received approval for three products: QLETLI® in China, and TOFIDENCE™/BAT1806 and Avzivi®/Pobevcy® in both the US and China. Additionally, Bio-Thera is progressing over 20 potential drug candidates in clinical trials, with a focus on immuno-oncology and targeted therapies post the PD-1 era.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Approves Theradaptive's IDE for Phase I/II Spinal Fusion Trials
Pharma Pioneer
3 min read
FDA Approves Theradaptive's IDE for Phase I/II Spinal Fusion Trials
31 May 2024
Therapeutic company Theradaptive has received approval from the U.S. FDA to initiate a global Phase I/II study for its spinal fusion product, OsteoAdapt SP.
Read →
Sirius Launches Phase 1 Trial for Innovative FXI siRNA Anticoagulant in Thromboembolic Treatment
Pharma Pioneer
2 min read
Sirius Launches Phase 1 Trial for Innovative FXI siRNA Anticoagulant in Thromboembolic Treatment
31 May 2024
Sirius Therapeutics has initiated a Phase 1 clinical trial for SRSD107, an innovative siRNA treatment aimed at preventing and managing thromboembolic disorders by targeting coagulation Factor XI (FXI).
Read →
Tharimmune Initiates Phase 1 Trial with TH104 for Treating Itch in Primary Biliary Cholangitis
Pharma Pioneer
2 min read
Tharimmune Initiates Phase 1 Trial with TH104 for Treating Itch in Primary Biliary Cholangitis
31 May 2024
The first individual has been administered TH104 in a Phase 1 clinical trial, focusing on the drug's safety, tolerability, and absolute bioavailability.
Read →
Sangamo Presents Positive Phase 1/2 Gene Therapy Data for Fabry Disease
Pharma Pioneer
2 min read
Sangamo Presents Positive Phase 1/2 Gene Therapy Data for Fabry Disease
31 May 2024
Sangamo Therapeutics has reported positive interim results from its Phase 1/2 STAAR clinical trial for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.